Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Perrigo Company PLC    PRGO   IE00BGH1M568

PERRIGO COMPANY PLC

(PRGO)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Perrigo : Buys Prevacid U.S. OTC Rights From GlaxoSmithKline

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/05/2019 | 09:10am EDT

By Chris Wack

Perrigo Company said Thursday it is buying the branded over-the-counter rights to Prevacid from GlaxoSmithKline.

Perrigo said under the terms of the agreement, it will have the exclusive rights to market, sell and distribute Prevacid 24HR in the U.S. OTC market.

Financial terms of the agreement weren't disclosed.

Prevacid 24HR treats frequent heartburn occurring two or more days a week.

Write to Chris Wack at chris.wack@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE -1.32% 1640 Delayed Quote.9.98%
PERRIGO COMPANY PLC 0.00% 55.96 Delayed Quote.44.41%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PERRIGO COMPANY PLC
09/06PERRIGO : Advances Consumer Self-Care Growth Strategy with Acquisition of Prevac..
AQ
09/05PERRIGO : Buys Prevacid U.S. OTC Rights From GlaxoSmithKline
DJ
08/29PERRIGO COMPANY PLC : Ex-dividend day for
FA
08/16PERRIGO : Sc 13d/a
PU
08/16PERRIGO CO PLC : Entry into a Material Definitive Agreement, Termination of a Ma..
AQ
08/08PERRIGO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
08/08PERRIGO CO PLC : Results of Operations and Financial Condition, Financial Statem..
AQ
08/08PERRIGO : 2Q Earnings Snapshot
AQ
08/07PERRIGO CO PLC : Change in Directors or Principal Officers (form 8-K)
AQ
07/16PERRIGO : Donates $50,000 to the Saugatuck Center for the Arts to Support an Ent..
AQ
More news
Financials (USD)
Sales 2019 4 791 M
EBIT 2019 802 M
Net income 2019 204 M
Debt 2019 2 758 M
Yield 2019 1,39%
P/E ratio 2019 43,3x
P/E ratio 2020 21,6x
EV / Sales2019 2,16x
EV / Sales2020 1,99x
Capitalization 7 614 M
Chart PERRIGO COMPANY PLC
Duration : Period :
Perrigo Company PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PERRIGO COMPANY PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Average target price 52,00  $
Last Close Price 55,96  $
Spread / Highest target 7,22%
Spread / Average Target -7,08%
Spread / Lowest Target -19,6%
EPS Revisions
Managers
NameTitle
Murray S. Kessler President, Chief Executive Officer & Director
Rolf Allan Classon Chairman
Ronald Janish Executive VP-Global Operations and Supply Chain
Ron L. Winowiecki Chief Financial Officer
Thomas Farrington Chief Information Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
PERRIGO COMPANY PLC44.41%7 614
JOHNSON & JOHNSON1.07%345 150
ROCHE HOLDING LTD.10.52%236 116
MERCK AND COMPANY8.11%211 513
PFIZER-15.44%204 151
NOVARTIS18.45%200 777